The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

ABSTRACT:

Background

Individuals with type 2 diabetes (T2D) are at greater risk of bone fractures than those without diabetes. Certain oral diabetic medications may further increase the risk of fracture. Dipeptidyl peptidase-IV (DPP-IV) inhibitors are incretin-based therapies that are being increasingly used for the management of T2D. It has been hypothesized that these agents may reduce fracture risk in those with T2D. In this study, we used a mouse model of T2D to examine the effects of the DPP-IV inhibitor, MK-0626, on bone.

Methods

Male wild type (WT) and diabetic muscle-lysine-arginine (MKR) mice were treated with MK-0626, pioglitazone, alendronate or vehicle. The effects of treatment with MK-0626 on bone microarchitecture and turnover were compared with treatment with pioglitazo

SUBMITTER: Gallagher EJ 

PROVIDER: S-EPMC5496098 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature